Oncodesign services

DRIVE-IDDS, an integrated drug discovery solution: a complete continuum from target to clinical candidate.

An extension of our innovation technology platforms, SOLO involves a wide range of distinct and diversified services. It covers an extensive spectrum of pharmaceutical expertise and the ability to design and carry out precise and ad hoc assessments in the discovery and development of new therapies.Drawing on our experience and expertise in the preclinical investigation of new therapeutic entities – with different mechanisms of action – in various indications, and given our mastery of cutting-edge translational technologies, our SOLO services are a guarantee of quality and excellence to meet various needs and specificities.

Establishing proof of concept in preclinical pharmacology is a critical step in the drug discovery process. This is one of the decisive factors in setting the therapeutic indication(s) targeted in clinical models and in the decision to continue a new product through the regulatory preclinical and clinical steps. For more than 25 years, Oncodesign has been a player known for its experience and excellence in preclinical pharmacology, particularly in vitro and in vivo testing, PK, PK/PD relationships and pharmaco-imaging applied to the identification and qualification of the therapeutic potential of many different approaches and techniques – chemical entities, peptides, oligonucleotides, biologics, gene and cell therapies, oncolytic viruses, vaccines and more.

Complementary expertise for successful progress at each stage of your development. After the discovery and proof-of-concept phases, the preclinical development of new therapeutic entities is a critical step for the regulatory approval of the first-in-man administration and the transition to the early phases of clinical trials. D-VLOP, a network of expert partners all renowned and experienced in preclinical and clinical development, is the solution to successfully complete this phase. Together with our partners Cynbiose, ERBC and PharmaLexwe bring you advice and support to define and implement your pre-clinical and clinical strategic program in line with your requirements and those of the regulatory authorities.

EXPLORE, a new service to identify and validate therapeutic targets, primarily cancer treatments – an area of expertise and excellence at Oncodesign to discover and investigate preclinical proofs of concept involving a wide variety of different approaches and anti-cancer mechanisms of action. EXPLORE, is the combination of our OncoSNIPER platform and a tailored and well established experimental validation process organized by indication and target.